Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
Sell
39
RHHBY Quote, Financials, Valuation and Earnings
Last price:
$41.92
Seasonality move
:
2.77%
Day range:
$41.69 - $42.13
52-week range:
$29.20 - $44.31
Dividend yield:
3.25%
P/E ratio:
29.21x
P/S ratio:
3.84x
P/B ratio:
7.59x
Volume:
5.2M
Avg. volume:
4.8M
1-year change:
31.33%
Market cap:
$266.7B
Revenue:
$70.9B
EPS (TTM):
$1.44
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RHHBY
Roche Holding AG
|
$16.9B | -- | -- | -- | $46.29 |
|
AMGN
Amgen
|
$8.9B | $5.08 | 8.14% | 257.4% | $315.95 |
|
AZN
AstraZeneca PLC
|
$14.2B | $1.04 | 7.95% | 57.32% | $85.19 |
|
LLY
Eli Lilly and
|
$13.4B | $5.07 | 45.83% | 90.33% | $1,010.47 |
|
NVO
Novo Nordisk AS
|
$11.5B | $0.80 | 19.55% | 6.88% | $106.57 |
|
NVS
Novartis AG
|
$12.8B | $1.76 | 6.64% | 57% | $109.37 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RHHBY
Roche Holding AG
|
$41.92 | $46.29 | $266.7B | 29.21x | $1.36 | 3.25% | 3.84x |
|
AMGN
Amgen
|
$306.95 | $315.95 | $164.9B | 40.66x | $2.38 | 2.97% | 4.96x |
|
AZN
AstraZeneca PLC
|
$73.79 | $85.19 | $228.8B | 32.72x | $1.05 | 2.1% | 4.26x |
|
LLY
Eli Lilly and
|
$822.51 | $1,010.47 | $738.8B | 70.24x | $1.50 | 0.66% | 16.51x |
|
NVO
Novo Nordisk AS
|
$69.30 | $106.57 | $307.6B | 21.11x | $0.52 | 2.09% | 7.35x |
|
NVS
Novartis AG
|
$112.57 | $109.37 | $222.3B | 19.14x | $3.87 | 3.44% | 4.43x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RHHBY
Roche Holding AG
|
52.17% | 0.691 | 16.91% | 1.19x |
|
AMGN
Amgen
|
91.09% | 0.434 | 43.85% | 0.84x |
|
AZN
AstraZeneca PLC
|
41.27% | -0.475 | -- | 0.74x |
|
LLY
Eli Lilly and
|
70.33% | 0.371 | 5.05% | 0.59x |
|
NVO
Novo Nordisk AS
|
40.09% | 0.871 | 3.51% | 0.52x |
|
NVS
Novartis AG
|
40.07% | 0.604 | 15.32% | 0.80x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RHHBY
Roche Holding AG
|
-- | -- | 12.15% | 23.8% | -- | -- |
|
AMGN
Amgen
|
$6B | $2.3B | 5.97% | 66.87% | 16.83% | $4.4B |
|
AZN
AstraZeneca PLC
|
$12.2B | $2B | 9.88% | 17.77% | 14.07% | $2B |
|
LLY
Eli Lilly and
|
$11.1B | $5.8B | 25.09% | 80.24% | 38.89% | $726.6M |
|
NVO
Novo Nordisk AS
|
$10.4B | $5.2B | 60.28% | 86.85% | 40.78% | -$786.4M |
|
NVS
Novartis AG
|
$10.2B | $3.5B | 16.91% | 27.64% | 26.26% | $3.1B |
Roche Holding AG vs. Competitors
-
Which has Higher Returns RHHBY or AMGN?
Amgen has a net margin of -- compared to Roche Holding AG's net margin of 6.9%. Roche Holding AG's return on equity of 23.8% beat Amgen's return on equity of 66.87%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $78.4B AMGNAmgen65.75% $1.16 $66B -
What do Analysts Say About RHHBY or AMGN?
Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 10.42%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could grow by 2.93%. Given that Roche Holding AG has higher upside potential than Amgen, analysts believe Roche Holding AG is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG3 4 0 AMGNAmgen9 14 2 -
Is RHHBY or AMGN More Risky?
Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.
-
Which is a Better Dividend Stock RHHBY or AMGN?
Roche Holding AG has a quarterly dividend of $1.36 per share corresponding to a yield of 3.25%. Amgen offers a yield of 2.97% to investors and pays a quarterly dividend of $2.38 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios RHHBY or AMGN?
Roche Holding AG quarterly revenues are --, which are smaller than Amgen quarterly revenues of $9.1B. Roche Holding AG's net income of -- is lower than Amgen's net income of $627M. Notably, Roche Holding AG's price-to-earnings ratio is 29.21x while Amgen's PE ratio is 40.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.84x versus 4.96x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG3.84x 29.21x -- -- AMGNAmgen4.96x 40.66x $9.1B $627M
-
Which has Higher Returns RHHBY or AZN?
AstraZeneca PLC has a net margin of -- compared to Roche Holding AG's net margin of 10.07%. Roche Holding AG's return on equity of 23.8% beat AstraZeneca PLC's return on equity of 17.77%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $78.4B AZNAstraZeneca PLC81.7% $0.48 $69.5B -
What do Analysts Say About RHHBY or AZN?
Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 10.42%. On the other hand AstraZeneca PLC has an analysts' consensus of $85.19 which suggests that it could grow by 15.45%. Given that AstraZeneca PLC has higher upside potential than Roche Holding AG, analysts believe AstraZeneca PLC is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG3 4 0 AZNAstraZeneca PLC6 2 0 -
Is RHHBY or AZN More Risky?
Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.758%.
-
Which is a Better Dividend Stock RHHBY or AZN?
Roche Holding AG has a quarterly dividend of $1.36 per share corresponding to a yield of 3.25%. AstraZeneca PLC offers a yield of 2.1% to investors and pays a quarterly dividend of $1.05 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBY or AZN?
Roche Holding AG quarterly revenues are --, which are smaller than AstraZeneca PLC quarterly revenues of $14.9B. Roche Holding AG's net income of -- is lower than AstraZeneca PLC's net income of $1.5B. Notably, Roche Holding AG's price-to-earnings ratio is 29.21x while AstraZeneca PLC's PE ratio is 32.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.84x versus 4.26x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG3.84x 29.21x -- -- AZNAstraZeneca PLC4.26x 32.72x $14.9B $1.5B
-
Which has Higher Returns RHHBY or LLY?
Eli Lilly and has a net margin of -- compared to Roche Holding AG's net margin of 32.59%. Roche Holding AG's return on equity of 23.8% beat Eli Lilly and's return on equity of 80.24%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $78.4B LLYEli Lilly and82.24% $4.88 $47.9B -
What do Analysts Say About RHHBY or LLY?
Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 10.42%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 22.85%. Given that Eli Lilly and has higher upside potential than Roche Holding AG, analysts believe Eli Lilly and is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG3 4 0 LLYEli Lilly and16 4 0 -
Is RHHBY or LLY More Risky?
Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.
-
Which is a Better Dividend Stock RHHBY or LLY?
Roche Holding AG has a quarterly dividend of $1.36 per share corresponding to a yield of 3.25%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBY or LLY?
Roche Holding AG quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Roche Holding AG's net income of -- is lower than Eli Lilly and's net income of $4.4B. Notably, Roche Holding AG's price-to-earnings ratio is 29.21x while Eli Lilly and's PE ratio is 70.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.84x versus 16.51x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG3.84x 29.21x -- -- LLYEli Lilly and16.51x 70.24x $13.5B $4.4B
-
Which has Higher Returns RHHBY or NVO?
Novo Nordisk AS has a net margin of -- compared to Roche Holding AG's net margin of 32.95%. Roche Holding AG's return on equity of 23.8% beat Novo Nordisk AS's return on equity of 86.85%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $78.4B NVONovo Nordisk AS84.8% $0.91 $33.4B -
What do Analysts Say About RHHBY or NVO?
Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 10.42%. On the other hand Novo Nordisk AS has an analysts' consensus of $106.57 which suggests that it could grow by 53.78%. Given that Novo Nordisk AS has higher upside potential than Roche Holding AG, analysts believe Novo Nordisk AS is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG3 4 0 NVONovo Nordisk AS4 3 1 -
Is RHHBY or NVO More Risky?
Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.420, suggesting its less volatile than the S&P 500 by 58.038%.
-
Which is a Better Dividend Stock RHHBY or NVO?
Roche Holding AG has a quarterly dividend of $1.36 per share corresponding to a yield of 3.25%. Novo Nordisk AS offers a yield of 2.09% to investors and pays a quarterly dividend of $0.52 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBY or NVO?
Roche Holding AG quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Roche Holding AG's net income of -- is lower than Novo Nordisk AS's net income of $4B. Notably, Roche Holding AG's price-to-earnings ratio is 29.21x while Novo Nordisk AS's PE ratio is 21.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.84x versus 7.35x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG3.84x 29.21x -- -- NVONovo Nordisk AS7.35x 21.11x $12.2B $4B
-
Which has Higher Returns RHHBY or NVS?
Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 20.79%. Roche Holding AG's return on equity of 23.8% beat Novartis AG's return on equity of 27.64%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $78.4B NVSNovartis AG75.48% $1.41 $73.6B -
What do Analysts Say About RHHBY or NVS?
Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 10.42%. On the other hand Novartis AG has an analysts' consensus of $109.37 which suggests that it could fall by -2.84%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG3 4 0 NVSNovartis AG0 9 2 -
Is RHHBY or NVS More Risky?
Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.528, suggesting its less volatile than the S&P 500 by 47.174%.
-
Which is a Better Dividend Stock RHHBY or NVS?
Roche Holding AG has a quarterly dividend of $1.36 per share corresponding to a yield of 3.25%. Novartis AG offers a yield of 3.44% to investors and pays a quarterly dividend of $3.87 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBY or NVS?
Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.6B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $2.8B. Notably, Roche Holding AG's price-to-earnings ratio is 29.21x while Novartis AG's PE ratio is 19.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.84x versus 4.43x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG3.84x 29.21x -- -- NVSNovartis AG4.43x 19.14x $13.6B $2.8B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
